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Abstract
Copy number variants (CNVs) have been strongly implicated in the genetic etiology of 
schizophrenia (SCZ). However, genome-wide investigation of the contribution of CNV to risk has 
been hampered by limited sample sizes. We sought to address this obstacle by applying a 
centralized analysis pipeline to a SCZ cohort of 21,094 cases and 20,227 controls. A global 
enrichment of CNV burden was observed in cases (OR=1.11, P=5.7×10−15), which persisted after 
excluding loci implicated in previous studies (OR=1.07, P=1.7 ×10−6). CNV burden was enriched 
for genes associated with synaptic function (OR = 1.68, P = 2.8 ×10−11) and neurobehavioral 
phenotypes in mouse (OR = 1.18, P= 7.3 ×10−5). Genome-wide significant evidence was obtained 
for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, 
proximal 16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate 
susceptibility and protective loci, which consisted predominantly of CNVs mediated by non-allelic 
homologous recombination.
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Introduction
Studies of genomic copy number variation (CNV) have established a role for rare genetic 
variants in the etiology of SCZ 1. There are three lines of evidence that CNVs contribute to 
risk for SCZ: genome-wide enrichment of rare deletions and duplications in SCZ cases 
relative to controls 2, 3, a higher rate of de novo CNVs in cases relative to controls4–6, and 
association evidence implicating a small number of specific loci (Supplementary Table 1). 
All CNVs that have been implicated in SCZ are rare in the population, but confer significant 
risk (odds ratios 2–60).
To date, CNVs associated with SCZ have largely emerged from mergers of summary data 
for specific candidate loci 7–9; yet even the largest genome-wide scans (sample sizes 
typically <10,000) remain under-powered to robustly confirm genetic association for the 
majority of pathogenic CNVs reported so far, particularly for those with low frequencies 
(<0.5% in cases) or intermediate effect sizes (odds ratios 2–10). It is important to address the 
low power of CNV studies with larger samples given that this type of mutation has already 
proven useful for highlighting some aspects of SCZ related biology 6, 10–13.
The limited statistical power provided by small samples is a significant obstacle in studies of 
rare and common genetic variation. In response, global collaborations have been formed in 
order to attain large sample sizes, as exemplified by a study by the Schizophrenia Working 
Group of the Psychiatric Genomics Consortium (PGC) which identified 108 independent 
schizophrenia associated loci 14. Recognizing the need for similarly large samples in studies 
of CNVs for psychiatric disorders, we formed the PGC CNV Analysis Group. Our goal was 
to enable large-scale analyses of CNVs in psychiatry using centralized and uniform 
methodologies for CNV calling, quality control, and statistical analysis. Here, we report the 
largest genome-wide analysis of CNVs for any psychiatric disorder to date, using datasets 
assembled by the Schizophrenia Working Group of the PGC.
Data processing and meta-analytic methods
Raw intensity data were obtained from 57,577 subjects from 43 separate datasets 
(Supplementary Table 2). After CNV calling and quality control (QC), 41,321 subjects were 
retained for analysis. We developed a centralized pipeline for systematic calling of CNVs for 
Affymetrix and Illumina platforms. (Methods and Supplementary Figure 1). The pipeline 
included multiple CNV callers run in parallel. Data from Illumina platforms were processed 
using PennCNV 15 and iPattern 16. Data from Affymetrix platforms were analyzed using 
PennCNV and Birdsuite 17.Two additional methods, iPattern and C-score 18, were applied to 
data from the Affymetrix 6.0 platform. In order to ensure proper normalization of the X 
chromosome, male and female subjects were normalized separately. The CNV calls from 
each program were converted to a standardized format and a consensus call set was 
constructed by merging CNV outputs at the sample level. Only CNV segments that were 
detected by all algorithms were retained. We performed QC at the platform level to exclude 
samples with poor probe intensity and/or an excessive CNV load (number and length). A 
final set of rare, high quality CNVs was defined as those >20kb in length, at least 10 probes, 
and <1% MAF.
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Genetic associations were investigated by case-control tests of CNV burden at four levels: 
(1) genome-wide (2) pathways, (3) genes, and (4) CNV breakpoints. Analyses controlled for 
SNP-derived principal components, sex, genotyping platform and data quality metrics. 
Multiple-testing thresholds for genome-wide significance were estimated from family-wise 
error rates drawn from permutation
Genome wide analysis of CNV burden
An elevated burden of rare CNVs among SCZ cases has been well established 2. We applied 
our meta-analytic framework to measure the consistency of overall CNV burden across 
genotyping platforms, and whether a measurable amount of CNV burden persists outside of 
previously implicated CNV regions. Consistent with previous estimates, the overall CNV 
burden was significantly greater among SCZ cases when measured as total Kb covered 
(OR=1.12, p = 5.7×10−15), genes affected (OR=1.21, p = 6.6×10−21), or CNV number 
(OR=1.03, p = 1×10−3). The burden signal above was driven by CNVs located within genes. 
Focusing heretofore on the number of genes affected by CNV, the burden metric with the 
strongest signal of enrichment in our study, the effect size was consistent across all 
genotyping platforms (Figure 1a). When we split by CNV type, the effect size for copy 
number losses (OR=1.40, p = 4×10−16) was greater than for gains (OR=1.12, p = 2×10−7) 
(Supplementary Figures 2 and 3). Partitioning by CNV frequency (based on 50% reciprocal 
overlap with the full call set, Methods), CNV burden was enriched among cases across a 
range of frequencies, up to counts of 80 (MAF = 0.4%) in the combined sample (Figure 1b). 
CNV burden results for individual cohorts are provided in Supplementary Figure 4. We 
observed no enrichment in CNV burden when considering only variants that did not overlap 
exons (Supplementary Figure 5)
A primary question in this study is the contribution of novel loci to the excess CNV burden 
in cases. After removing nine previously implicated CNV loci (where reported p-values 
exceed our designated multiple testing threshold, Supplementary Table 1), excess CNV 
burden in SCZ remained significantly enriched (genes affected OR=1.11, p = 1.3×10−7, 
Figure 1b). CNV burden also remained significantly enriched after removal of all reported 
loci from Supplementary Table 1, but the effect-size was greatly reduced (OR = 1.08) 
compared to the enrichment overall (OR = 1.21). When we partitioned CNV burden by 
frequency, we found that much of the previously unexplained signal was restricted to ultra-
rare events (i.e., MAF < 0.1%, Figure 1b).
Gene-set (pathway) burden
We assessed whether CNV burden was concentrated within defined sets of genes involved in 
neurodevelopment or neurological function. A total of 36 gene-sets were evaluated (for a 
description see Supplementary Table 3), consisting of gene-sets representing neuronal 
function, synaptic components and neurological and neurodevelopmental phenotypes in 
human (19 sets), gene-sets based on brain expression patterns (7 sets), and human orthologs 
of mouse genes whose disruption causes phenotypic abnormalities, including 
neurobehavioral and nervous system abnormality (10 sets). Genes not expressed in brain (1 
set) or associated with abnormal phenotypes in mouse organ systems unrelated to brain (7 
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sets) were included as negative controls. We mapped CNVs to genes if they overlapped by at 
least one exonic basepair.
Gene-set burden was tested using logistic regression deviance test 6. In addition to using the 
same covariates included in genome-wide burden analysis, we controlled for the total 
number of genes per subject spanned by rare CNVs to account for signal that merely reflects 
the global enrichment of CNV burden in cases 19. Multiple-testing correction (Benjamini-
Hochberg False Discovery Rate, BH-FDR) was performed separately for each gene-set 
group and CNV type (gains, losses). After multiple test correction (Benjamini-Hochberg 
FDR ≤ 10%) 15 gene-sets were enriched for rare loss burden in cases and 4 for rare gains in 
cases, none of which are negative control sets (Figure 2).
Of the 15 sets significant for losses, the majority consisted of synaptic or other neuronal 
components (9 sets); in particular, “GO synaptic” (GO:0045202) and the activity-regulated 
cytoskeleton-associated protein complex, or “ARC complex”, rank first based on statistical 
significance and effect-size respectively (Figure 2a). Losses in cases were also significantly 
enriched for genes involved in nervous system or behavioral phenotypes in mouse but not for 
gene-sets related to other organ system phenotypes (Figure 2c). To account for dependency 
between synaptic and neuronal gene-sets, we re-tested loss burden following a step-down 
logistic regression approach, ranking gene-sets based on significance or effect size 
(Supplementary Table 4). Only GO synaptic and ARC complex were significant in at least 
one of the two step-down analyses, suggesting that burden enrichment in the other neuronal 
categories is mostly captured by the overlap with synaptic genes. Following the same 
approach, the mouse neurological/neurobehavioral phenotype set remained nominally 
significant, suggesting that a portion of this signal was independent of the synaptic gene set. 
Pathway enrichment was less pronounced for duplications, consistent with the smaller 
burden effects for this class of CNV. Among synaptic or other neuronal components, 
duplication burden was significantly enriched only for NMDA receptor complex; (Figure 
2b); none of the mouse phenotype sets passed the significance threshold for duplications 
(Figure 2d).
Given that synaptic gene sets were robustly enriched for deletions in cases, and with an 
appreciable contribution from loci that have not been strongly associated with SCZ 
previously, pathway-level interactions of these sets were further investigated. A protein-
interaction network was seeded using the synaptic and ARC complex genes that were 
intersected by rare deletions in this study (Figure 3). A graph of the network highlights 
multiple subnetworks of synaptic proteins including pre-synaptic adhesion molecules 
(NRXN1, NRXN3), post-synaptic scaffolding proteins (DLG1, DLG2, DLGAP1, SHANK1, 
SHANK2), glutamatergic ionotropic receptors (GRID1, GRID2, GRIN1, GRIA4), and 
complexes such as Dystrophin and its synaptic interacting proteins (DMD, DTNB, SNTB1, 
UTRN). A subsequent test of the Dystrophin glycoprotein complex (DGC) revealed that 
deletion burden of the synaptic DGC proteins (intersection of “GO DGC” GO:0016010 and 
“GO synapse” GO:0045202) was enriched in cases (Deviance test P = 0.05), but deletion 
burden of the full DGC was not significant (P = 0.69).
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Gene CNV association
To define specific loci that confer risk for SCZ, we tested CNV association at the level of 
individual genes, using logistic regression deviance test and the same covariates included in 
genome-wide burden analysis. To correctly account for large CNVs that affect multiple 
genes, we aggregated adjacent genes into a single locus if their copy number was highly 
correlated across subjects (more than 50% subject overlap). CNVs were mapped to genes if 
they overlapped one or more exons. The criterion for genome-wide significance used the 
Family-Wise Error Rate (FWER) < 0.05. The criterion for suggestive evidence used a 
Benjamini-Hochberg False Discovery Rate (BH-FDR) < 0.05.
Of eighteen independent CNV loci with gene-based BH-FDR < 0.05, two were excluded 
based on CNV calling accuracy or evidence of a batch effect (Supplementary Note). The 
sixteen loci that remain after these additional QC steps, comprising seventeen separate 
association signals, are listed in Table 1. P-values for this summary table were obtained by 
re-running our statistical model across the entire region (Supplementary Note). These 
sixteen loci represent a set of novel (n=6), previously reported (n=4), and previously 
implicated (n=7) regions, with 22q11.21 comprising two separate association signals at the 
same locus. Manhattan plots of the gene association for losses and gains are provided in 
Figure 4. A permutation-based false discovery rate yielded similar estimates to BH-FDR.
Eight loci attain genome-wide significance, including copy number losses at 1q21.1, 2p16.3 
(NRXN1), 3q29, 15q13.3, 16p11.2 (distal) and 22q11.2 along with gains at 7q11.23 and 
16p11.2 (proximal). An additional eight loci meet criterion for suggestive association, 
including six that have not been reported previously in association with SCZ. Based on our 
estimation of False Discovery Rates (BH and permutations), we expect to observe less than 
two associations meeting suggestive criteria by chance. In order to further evaluate the six 
new candidate loci identified here, we performed experimental validation of CNV calls in a 
subset of samples by digital droplet PCR (ddPCR, see Methods). Validation rates of 100% 
were obtained for gains of DMRT1, MAGEA11 and distal Xq28, losses of VPS13B, and 
gains and losses of ZNF92 (Supplementary Table 5). We obtained a low validation rate at 
one locus, ZMYM5 (64%), and therefore do not consider the association at this locus 
convincing.
Breakpoint level CNV association
With our sample size and uniform CNV calling pipeline, many individual CNV loci can be 
tested with adequate power at the CNV breakpoint level (i.e. the SNP probe defining the 
start and end of the CNV segment), potentially facilitating discovery at a finer resolution 
than locus-wide tests. Tests for association were performed at each CNV breakpoint using 
the residuals of case-control status after controlling for analysis covariates, with significance 
determined through permutation. Results for losses and gains are shown in Supplementary 
Figure 6. Four independent CNV loci surpass genome-wide significance, all of which were 
also identified in the gene-based test, including the 15q13.2–13.3 and 22q11.21 deletions, 
16p11.2 duplication, and 1q21.1 deletion and duplication. While these loci represent fewer 
than half of the previously implicated SCZ loci, we do find support for all loci where the 
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association originally reported meets the criteria for genome-wide correction in this study. 
We examined association among all previously reported loci showing association to SCZ, 
including 18 CNV losses and 25 CNV gains (Supplementary Table 6); 8 loci have BH-FDR 
q-value < 0.05, 13 loci have BH-FDR q-value < 0.1, and 25 of the 42 loci were associated 
with SCZ at an uncorrected p < .05.
Associations at some loci become better delineated through breakpoint-level analysis. For 
instance, NRXN1 at 2p16.3 is a CNV hotspot, and exonic deletions of this gene are 
significantly enriched in SCZ9, 20. In this large sample, we observe a high density of “non-
recurrent” deletion breakpoints in cases and controls. A snapshot of the breakpoint 
association results from the PGC CNV browser (see URLs) reveals a saw-tooth pattern of 
association. Predominant peaks correspond to exons and transcriptional start sites of 
NRXN1 isoforms (Figure 5). This example highlights how, with high diversity of alleles at a 
single locus, the association peak may become more refined, and in some cases converge 
toward individual functional elements. Similarly, visualization of the previously reported 
SCZ risk loci on 16p13.2 and 8q11.23 reveals a high density of duplication breakpoints, 
which better delineate genes in these regions. It is important, however, to note that CNV 
breakpoints in the current study are estimated from genotyped SNPs around the true 
breakpoint, and that these breakpoint estimates are limited by the resolution of the 
genotyping platform, and therefore subject to error.
Novel risk alleles are predominantly NAHR-mediated CNVs
Many CNV loci that have been strongly implicated in human disease are hotspots for non-
allelic homologous recombination (NAHR), a process which in most cases is mediated by 
flanking segmental duplications 21. We defined a CNV as “NAHR” when both the start and 
end breakpoint is located within a segmental duplication. Consistent with the importance of 
NAHR in generating CNV risk alleles for schizophrenia, most of the loci in Table 1 are 
flanked by segmental duplications. Moreover, after excluding loci that have been implicated 
in previous studies, the remaining loci with FDR < 0.05 in the gene-base burden test were 
NAHR enriched (6.03-fold, P=0.008; Supplementary Figure 7), when compared to a null 
distribution determined by randomizing the genomic positions of associated genes 
(Supplemental Note). These findings suggest that the novel SCZ CNVs share similar 
characteristics to known pathogenic CNVs in that they tend to occur in regions prone to high 
rates of recurrent mutation.
Discussion
The present study of the PGC SCZ CNV dataset includes the majority of all microarray data 
that has been generated in genetic studies of SCZ to date. In this, we find definitive evidence 
for eight loci, surpassing strict genome-wide multiple testing correction. We also find 
evidence for a contribution of novel CNVs conferring either risk or protection to SCZ, with 
an FDR < 0.05. The complete results, including CNV calls and statistical evidence at the 
gene or breakpoint level, can be viewed using the PGC CNV browser (URLs). Our data 
suggest that the undiscovered novel risk loci that can be detected with current genotyping 
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platforms lie at the ultra-rare end of the frequency spectrum and still larger samples will be 
needed to identify them at convincing levels of statistical evidence.
Collectively, the eight SCZ risk loci that surpass genome-wide significance are carried by a 
small fraction (1.4%) of SCZ cases in the PGC sample. We estimate 0.85% of the variance 
in SCZ liability is explained by carrying a CNV risk allele within these loci (Supplementary 
Note). As a comparison, 3.4% of the variance in SCZ liability is explained by the 108 
genome-wide significant loci identified in the companion PGC GWAS analysis. Combined, 
the CNV and SNP loci that have been identified to date explain a small proportion (<5%) of 
heritability. The large dataset here provides an opportunity to evaluate the strength of 
evidence for a variety of loci where an association with SCZ has been reported previously. 
Of 44 published findings from the recent literature, we find evidence for 8 loci at a false 
discovery rate of 5% and nominal support for an additional 17 loci (uncorrected p < 0.05, 
Supplementary Table 6). Thus, nearly half of the existing candidate loci retain some support 
in our combined analysis. However we also find a lack of evidence for many of the 
previously identified loci, underscoring the value of meta-analytic efforts to assess the 
validity of such reports. A lack of strong evidence in this dataset (which includes samples 
that overlap with many of the previous studies) may in some cases simply reflect that 
statistical power is limited for very rare variants, even in large samples. However, it is likely 
that some of the earlier findings represent chance associations; indeed, the loci that are not 
supported by our data consist largely of loci for which the original statistical evidence was 
weak (Supplementary Table 6). Thus, our results help to refine the list of promising 
candidate CNVs. Continued efforts to evaluate the growing number of candidate variants has 
considerable value for directing future research efforts focused on specific loci.
The novel candidate loci meeting suggestive criteria in this study include two regions on 
chromosome X. It has been hypothesized that sex-linked loci contribute to SCZ, based 
originally on the observation of an increased rate of sex chromosome aneuploidy in cases 22. 
X-linked loci could not be detected in previous CNV studies of SCZ, because none to date 
evaluated variants on the sex chromosomes. In the current study, accurate calls were 
obtained by controlling for sex chromosome ploidy in the normalization and variant calling 
methods. Notably, duplications of distal Xq28 (regional P = 3.6×10−4, OR = 8.9, Table 1 and 
Supplementary Figure 8) appear to confer risk for SCZ in both males and females, and the 
effect size was greatest in males (P = 0.01, OR = ∞). Similar patterns consistent with 
dominant X-linked effects were observed at other loci (Supplementary Table 7). 
Duplications of distal Xq28 have been reported in association with developmental delay in 
both sexes 23, 24. Notably, of 26 subjects that have been described clinically, nearly half 
(12/26) have behavioral or psychiatric conditions. Of the five reciprocal deletions that were 
detected in this study, none were observed in males, consistent with hemizygous loss of 
distal Xq28 being associated with recessive embryonic lethality in males 24. Thus, mounting 
evidence indicates that increased copy number of distal Xq28 is associated with psychiatric 
illness. These results also provide a further demonstration that CNV risk factors in 
schizophrenia overlap with loci that contribute to pediatric developmental disorders 1, 25.
We observed multiple “protective” CNVs that showed a suggestive enrichment in controls, 
including duplications of 22q11.2, and MAGEA11 along with deletions and duplications of 
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ZNF92. No protective effects were significant after genome-wide correction. Moreover, a 
rare CNV that confers reduced risk for SCZ may not confer a general protection from 
neurodevelopmental disorders. For example, microduplications of 22q11.2 appear to confer 
protection from SCZ 26; however, such duplications have been shown to increase risk for 
developmental delay and a variety of congenital anomalies in pediatric clinical 
populations 27. It is probable that some of the undiscovered rare alleles affecting risk for 
SCZ confer protection but larger sample sizes are needed to determine this unequivocally. If 
it is true that a proportion of CNVs observed in our control sample represent rare protective 
alleles, then the heritability of SCZ explained by CNVs may not be fully accounted for by 
the excess CNV burden in cases.
Our results provide strong evidence that deletions in SCZ are enriched within a highly 
connected network of synaptic proteins, consistent with previous studies 2, 6, 10, 28. The large 
CNV dataset here allows a more detailed view of the synaptic network and highlights 
subsets of genes account for the excess deletion burden in SCZ, including synaptic cell 
adhesion and scaffolding proteins, glutamatergic ionotropic receptors and protein complexes 
such as the ARC complex and DGC. Modest CNV evidence implicating Dystrophin (DMD) 
and its binding partners is intriguing given that the involvement of certain components of the 
DGC have been postulated 29, 30 and disputed 31 previously. Larger studies of CNV are 
needed to define a role for this and other synaptic sub-networks in SCZ.
Our current study is well-powered to detect CNVs of large effect that occur in >0.1% of 
cases, but is underpowered to detect association to variants with modest effect sizes or to 
ultra-rare variants regardless of effect size. Furthermore, this study did not assess the 
contribution of common CNVs to SCZ, one instance of which we know: a recent study has 
demonstrated that the causal variants underlying the strongest common variant association in 
SCZ include duplications of Complement factor 4A 35. Lastly, we recognize that a majority 
of structural variants (SVs) are not detectable with current genotyping platforms 32. New 
technologies for whole genome sequencing will ultimately provide an assessment of the 
contribution of a wider array of rare variants including balanced rearrangements, small 
CNVs 33 and short tandem repeats 34.
This study represents a milestone. Large-scale collaborations in psychiatric genetics have 
greatly advanced discovery through genome-wide association studies. Here we have 
extended this framework to rare CNVs. Our knowledge of the contribution from lower 
frequency variants gives us confidence that the application of this framework to large newly 
acquired datasets has the potential to further the discovery of loci and identification of the 
relevant genes and functional elements.
Methods
Overview
We assembled a CNV analysis group with the goal of leveraging the extensive expertise 
within the Psychiatric Genomics Consortium (PGC) to develop a fully automated centralized 
pipeline for consistent and systematic calling of CNVs for both Affymetrix and Illumina 
platforms. An overview of the analysis pipeline is shown in Supplementary Figure 1. After 
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an initial data formatting step we constructed batches of samples for processing using four 
different methods, PennCNV, iPattern, C-score (GADA and HMMSeg) and Birdsuite for 
Affymetrix 6.0. For Affymetrix 5.0 data we used Birdsuite and PennCNV, for Affymetrix 
500 we used PennCNV and C-score, and for all Illumina arrays we used PennCNV and 
iPattern. We then constructed a consensus CNV call dataset by merging data at the sample 
level and further filtered calls to make a final dataset Supplementary Table 2. Prior to any 
filtering, we processed raw genotype calls for a total of 57,577 individuals, including 28,684 
SCZ cases and 28,893 controls.
Study Sample
A complete list of datasets that were included in the current study can be found in 
Supplementary Table 2. A more detailed description of the original studies can be found in a 
previous publication1
Copy Number Variant Analysis Pipeline Architecture and Sample Processing
All aspects of the CNV analysis pipeline were built on the Genetic Cluster Computer (GCC) 
in the Netherlands https://userinfo.surfsara.nl/systems/lisa.
Input Acceptance and Preprocessing—For Affymetrix we used the *.CEL files (all 
converted to the same format) as input, whereas for Illumina we required Genome or 
Beadstudio exported *.txt files with the following values: Sample ID, SNP Name, Chr, 
Position, Allele1 – Forward, Allele2 – Forward, X, Y, B Allele Freq and Log R Ratio. 
Samples were then partitioned into ‘batches’ to be run through each pipeline. For Affymetrix 
samples we created analysis batches based on the plate ID (if available) or genotyping date. 
Each batch had approximately 200 samples. Each batch included at least 50 subjects of each 
sex. Affymetrix Power Tools (APT - apt-copynumber-workflow) was then used to calculate 
summary statistics about chips analyzed. Gender mismatches identified and excluded as 
were experiments with MAPD > 0.4. For Illumina data, we first determined the genome 
build and converted to hg18 if necessary and created analysis batches based on the plate ID 
or genotyping date.
Composite Pipeline—The composite pipeline comprises CNV callers PennCNV 2, 
iPattern 3, Birdsuite 4 and C-Score 5 organized into component pipelines. We used all four 
callers for Affymetrix 6.0 data and we used PennCNV and C-Score for Affymetrix 500. 
Probe annotation files were preprocessed for each platform. Once the array design files and 
probe annotation files were pre-processed, each individual pipeline component pipeline was 
run in two steps: 1) processing the intensity data by the core pipeline process to produce 
CNV calls, 2) parsing the specific output format of the core pipeline and converting the calls 
to a standard form designed to capture confidence scores, copy number states and other 
information computed by each pipeline
Merging of CNV data and Quality control (QC) filtering—Merging of CNV data and 
Quality control (QC) filtering is described in detail in the supplementary material. Briefly, 
for each subject CNV calls were made using multiple algorithms. Only CNV calls that were 
made using multiple algorithms were included in the call set. Sample level QC filtering was 
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performed by removing arrays with excessive probe variance or GC bias and removal of 
samples with mismatches in gender or ethnicity or chromosomal aneuploidies. The final 
filtered CNV dataset was annotated with Refseq genes (transcriptions and exons). After this 
stage of quality control (QC), we had a total of 52,511 individuals, with 27,034 SCZ cases 
and 25,448 controls. To make our final dataset of rare CNVs for all subsequent analysis we 
filtered out variants that were present at >= 1% (50% reciprocal overlap) frequency in cases 
and controls combined. We included in the call set CNVs that were ≥20 kb and ≥10 probes 
in length and overlapped < 50% with regions tagged as copy number polymorphic on any 
other platform.
In order to minimize the impact of technical artifacts and potential confounds on CNV 
association results, we removed from the dataset individuals that did not pass QC filtering 
from the companion PGC GWAS study of schizophrenia 1 as well as well as case or control 
samples that could not be matched by array platform or reconciled by using a common set of 
probes.
Statistics
Regression of potential confounds on case-control ascertainment—The PGC 
cohorts are a combination of many datasets drawn from the US and Europe, and it is 
important to ensure that any bias in sample ascertainment does not drive spurious association 
to SCZ. In order to ensure the robustness of the analysis, burden and gene-set analyses 
included potential confounding variables as covariates in a logistic regression framework. 
Due to the number of tests run at breakpoint level association, we employed a step-wise 
logistic regression approach to allow for the inclusion of covariates in our case-control 
association, which we term the SCZ residual phenotype.
Covariates included sex, genotyping platform, and ancestry principal components derived 
from SNP genotypes on the same samples in a previous study1. Control for population 
stratification is described in the supplementary material. We were unable to control for 
dataset or genotyping batch, as a subset of the contributing datasets are fully confounded 
with case/control status. Only principal components that showed a significant association to 
small CNV burden were used (small CNV being defined as autosomal CNV burden with 
CNV < 100 kb in size). Among the top 20 principal components, only the 1st, 2nd, 3rd, 4th, 
and 8th principal component showed association with small CNV burden (with p < 0.01 used 
as the significance cutoff).
Lastly, in order to control for case-control differences in CNV ascertainment due to data 
quality we sought to identify data quality metrics that were confounded with case status. 
Affymetrix (MAPD and waviness-sd) and Illumina (LRRSD, BAFSD, GCWF) QC metrics 
were re-examined across studies to assess if any additional outliers were present. Only three 
outliers were removed as their mean B allele (or minor allele) frequency deviated 
significantly from 0.5. Many CNV metrics are auto-correlated, as they measure similar 
patterns of variation in the probe intensity. Thus, we focused on the primary measure of 
probe variance – MAPD and LRRSD. Among Affymetrix 6.0 datasets, MAPD did not differ 
between in cases and controls (t=1.14, p = 0.25). However, among non-Affymetrix 6.0 
datasets, LRRSD showed significant differences between cases and controls (t=−35.3, p < 
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2e−16), with controls having a higher standardized mean LRRSD (0.227) than cases 
(−0.199). Thus, to control for any spurious associations driven by CNV calling quality, we 
included MAPD (for Affymetrix platforms) or LRRSD (for Illumina platforms) as covariates 
in downstream analysis, which we designate as our “CNV metric” covariate for each 
individual. Prior to inclusion in the combined dataset, the CNV metric variable was 
normalized within each respective genotyping platform.
To calculate the SCZ residual phenotype, we first fit a logistic regression model of covariates 
to affection status, and then extracted the Pearson residual values for use in a quantitative 
association design for downstream analyses. Residual phenotype values in cases are all 
above zero, and controls below zero, and are graphed against overall kb burden in 
Supplementary Figure 9. We removed three individuals with an SCZ residual phenotype 
greater than three (or negative three in controls). After the post-processing round of QC, we 
retained a dataset with a total of 41,321 individuals comprising 21,094 SCZ cases and 
20,227 controls.
CNV burden analysis—We analyzed the overall CNV burden in a variety of ways to 
discern which general properties of CNV are contributing to SCZ risk. Overall individual 
CNV burden was measured in 3 distinct ways – 1) Kb burden of CNVs, 2) Number of genes 
affected by CNVs, and 3) Number of CNVs. Genes were counted only if the CNV 
overlapped a coding exon. We also partitioned our analyses by CNV type, size, and 
frequency. CNV type is defined as copy number losses (or deletions), copy number gains (or 
duplications), and both copy number losses and gains. To assign a specific allele frequency 
to a CNV, we used the --cnv-freq-method2 command in PLINK, whereby the frequency is 
determined as the total number of CNV overlapping the target CNV segment by at least 
50%. This method differs from other methods that assign CNV frequencies by genomic 
region, whereby a single CNV spanning multiple regions may be included in multiple 
frequency categories.
For Figure 1, and Supplementary Figures 2 and 3, we partitioned CNV burden by 
genotyping platform, and the abbreviations for each platform are expanded below:
A500: Affymetrix 500
I300: Illumina 300K
I600: Illumina 610K and Illumina 660W
A5.0: Affymetrix 5.0
A6.0: Affymetrix 6.0
omni: OmniExpress and OmniExpress plus Exome
Due to the small sample size of the Omni 2.5 array (28 cases and 10 controls), they were 
excluded from presentation in the figure, but are included in all burden analyses with the 
total PGC sample. Using a logistic regression framework with the inclusion of covariates 
detailed above, we predicted SCZ status using CNV burden as an independent predictor 
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variable, thus allowing us to get an accurate estimate of the contribution of CNV burden. In 
addition, to determine the proportion of CNV burden risk that is attributable to loci that have 
not been implicated in previous studies of SCZ, we ran all burden analyses after removing 
CNVs that overlapped previously implicated CNV boundaries by more than 10%.
CNV breakpoint level association—Association was tested at each respective CNV 
breakpoint. Three categories of CNV were tested: deletions, duplications, and deletions and 
duplications combined. All analyses were run using PLINK6.
We ran breakpoint level association using the SCZ residual phenotype as a quantitative 
variable, with significance determined through permutation of phenotype residual labels. An 
additional z-scoring correction, explained below, is used to control for any extreme values in 
the SCZ residual phenotype and efficiently estimate two-sided empirical p-values for highly 
significant loci. To ensure against the potential loss of power from the inclusion of 
covariates, we also ran a single degree of freedom Cochran-Mantel-Haenzel (CMH) test 
stratified by genotyping platform, with a 2 (CNV carrier status) × 2 (phenotype status) × N 
(genotyping platform) contingency matrix. While the CMH test does not account for more 
subtle biases that could drive false positive signals, it is robust to signals driven by a single 
platform and allows for each CNV carrier to be treated equally. Loci the surpassed genome-
wide correction in either test was followed up for further evaluation.
Z-score recalibration of empirical testing: Breakpoint level association p-values from the 
SCZ residual phenotype were initially obtained by performing one million permutations at 
each CNV position, whereby each permutation shuffles the SCZ residual phenotype among 
all samples, and retains the SCZ residual mean for CNV carriers and non-carriers. For 
extremely rare CNV, however, CNV carriers at the extreme ends of the SCZ residual 
phenotype can produce highly significant p-values. While we understand that such rare 
events are unable to surpass strict genome-wide correction, we wanted to retain all tests to 
help delineate the potential fine-scale architecture within a single region of association. To 
properly account for the increased variance when only a few individuals are tested, we 
applied an empirical Z-score correction to the CNV carrier mean. In order to get an 
empirical estimate of the variance for each test, we calculated the standard deviation of 
residual phenotype mean differences in CNV carriers and non-carriers from 5,000 
permutations. Z-scores are calculated as the observed case-control mean difference divided 
by the empirical standard deviation, with corresponding p-values calculated from the 
standard normal distribution. Concordance of the initial empirical and Z-score p-values are 
close to unity for association tests with six or more CNV, whereas Z-score p-values are more 
conservative among tests with less than six CNV. Furthermore, the Z-score method naturally 
provides an efficient manner to estimate highly significant empirical p-values that would 
involve hundreds of millions of permutations to achieve. Genome-wide correction for 
multiple testing was determined as described in the Supplementary Note
Gene-set burden enrichment analysis: gene-sets—Gene-sets with an a priori 
expectation of association to neuropsychiatric disorders were compiled and CNV calls were 
preprocessed as described in the supplementary material.
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For each gene-set, we fit the following logistic regression model (as implemented by the R 
function glm of the stats package), where subjects are statistical sampling units:
y ~ covariates + global + gene-set
Where:
• y is the dicotomic outcome variable (schizophrenia = 1, control = 0)
• covariates is the set of variables used as covariates also in the genome-wide 
burden and breakpoint association analysis (sex, genotyping platform, CNV 
metric, and CNV associated principal components)
• global is the measure of global genic CNV burden. This covariate accounts for 
non-specific association signal that could be merely reflective of an overall 
difference CNV burden between cases and controls. For the results in the main 
text, we used the total gene number (abbreviated as U from universe gene-set 
count); we also calculated results for total length (abbreviated as TL) and variant 
number plus variant mean length (abbreviated as CNML)
• gene-set is the gene-set gene count
The gene-set burden enrichment was assessed by performing a chi-square deviance test (as 
implemented by the R function anova.glm of the stats package) comparing these two 
regression models:
y ~ covariates + global
y ~ covariates + global + gene-set
We reported the following statistics:
• coefficient beta estimate (abbreviated as Coeff)
• t-student distribution-based coefficient significance p-value (as implemented by 
the R function summary.glm of the stats package, abbreviated as Pvalue_glm)
• deviance test p-value (abbreviated as Pvalue_dev)
• gene-set size (i.e. number of genes is the gene-set, regardless of CNV data)
• BH-FDR (Benjamini-Hochberg False Discovery rate)
• percentage of schizophrenia and control subjects with at least 1 gene, 2 genes, 
etc… impacted by a CNV of the desired type (loss or gain) in the gene-set 
(abbreviated as SZ_g1n, SZ_g2n, … CT_g1n, …)
Please note that, by performing simple simulation analyses, we realized that Pvalue_glm can 
be extremely over-conservative in presence of very few gene-set counts different than 0, 
while Pvalue_dev tends to be slightly under-conservative. While the two p-values tend to 
agree well for gene-set analysis, Pvalue_glm is systematically over-conservative for gene 
analysis since smaller counts are typically available for single genes.
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Gene association analysis—Subjects were restricted to the ones with at least one rare 
CNV. Only genes with at least a minimum number of subjects impacted by CNV were 
tested; this threshold was picked by comparing the BH-FDR to the permutation-based FDR 
and ensuring limited FDR inflation (permuted FDR < 1.65 * BH-FDR at BH-FDR threshold 
= 5%) while maximizing power. For gains the threshold was set to 12 counts, while for 
losses it was set to 8 counts.
For each gene, we fit the following logistic regression model (as implemented by the R 
function glm of the stats package), where subjects are statistical sampling units:
y ~ covariates + gene
Where:
• y is the dichotomous outcome variable (schizophrenia = 1, control = 0)
• covariates is the set of variables used as covariates also in the genome-wide 
burden and breakpoint association analysis (sex, genotyping platform, CNV 
metric, and CNV associated principal components)
• gene is the binary indicator for the subject having or not having a CNV of the 
desired type (loss or gain) mapped to the gene
The gene burden was assessed by performing a chi-square deviance test (as implemented by 
the R function anova.glm of the stats package) comparing these two regression models:
• y ~ covariates
• y ~ covariates + gene
Genome wide correction for multiple testing was determined as described in the 
supplementary material.
Experimental Validation of CNV calls by digital droplet PCR—For 6 novel 
candidate loci that were identified in this study, we sought to confirm CNV calling accuracy 
by experimental validation of CNV calls in a subset of study samples. Within each 
association peak we a defined a segment was defined that overlapped a majority of calls. 
Appropriate digital droplet assays were then selected from the BioRad catalog. A single 
FAM-labeled probe was designed for DMRT1, ZMYM5, ZNF92, MAGEA11 and Distal 
Xq28. Because some deletions of the VPS13B gene were non-overlapping, two different 
probes were selected for this locus. CNV calls (up to a maximum of 17) were selected from 
the core target region. Probe details, CNV calls and validation results can be found in 
Supplementary Table 5. Study samples were then obtained from two studies (Sweden and 
CLOZUK) and 4 population control samples were obtained from Coriell Cell repositories 
(ND00745, ND01936, ND00689, ND01317) to be used as negative controls for ddPCR 
assays. EcoRI digested samples (10 ng of genomic DNA) were analyzed in triplicate by 
ddPCR using the Fam-labeled CNV probe and HEX-labeled reference probe M0005 RPP30-
HEX (Supplementary Table 5) in the UCSD CFAR Genomics & Sequencing Core. PCR 
droplets were generated using a Bio-Rad QX100 Droplet Generator, then quantitative PCR 
was performed using the GeneAmp PCR system 9700 (Applied Biosystems) instrument 
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according to manufacturer’s protocols (40 cycles at 94°C for 30 sec and 60°C for 1 min). 
PCR droplets were read & analyzed on Bio-Rad QX100 Droplet Reader with QuantaSoft 
software.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CNV Burden
(A) Forest plot of CNV burden (measured here as genes affected by CNV), partitioned by 
genotyping platform, with the full PGC sample at the bottom. CNV burden is calculated by 
combining CNV gains and losses. Numbers of case and controls for each platform are listed, 
and “genes” denotes the mean number of genes affected by a CNV in controls. Burden tests 
use a logistic regression model predicting SCZ case/control status by CNV burden along 
with covariates (see methods). The odds ratio is the exponential of the logistic regression 
coefficient, and odds ratios above one predict increased SCZ risk. (B) CNV burden 
partitioned by CNV frequency. For reference, for autosomal CNVs, a CNV count of 41 in 
Marshall et al. Page 25
Nat Genet. Author manuscript; available in PMC 2017 December 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the sample corresponds to frequency of 0.1% in the full PGC sample. Using the same model 
as above, each CNV was placed into a single CNV frequency category based on a 50% 
reciprocal overlap with other CNVs. CNV gene burden with inclusion of all CNVs are 
shown in green, and burden excluding previously implicated CNV loci are shown in blue.
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Figure 2. Gene-set Burden
Gene-set burden test results for rare losses (a, c) and gains (b, d); frames a–b display gene-
sets for neuronal function, synaptic components, neurological and neurodevelopmental 
phenotypes in human; frames c–d display gene-sets for human homologs of mouse genes 
implicated in abnormal phenotypes (organized by organ systems); both are sorted by –log 10 
of the logistic regression deviance test p-value multiplied by the beta coefficient sign, 
obtained for rare losses when including known loci. Gene-sets passing the 10% BH-FDR 
threshold are marked with “*”. Gene-sets representing brain expression patterns were 
omitted from the figure because only a few were significant (losses: 1, gains: 3).
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Figure 3. Protein Interaction Network for Synaptic Genes
Synaptic and ARC-complex genes intersected by a rare loss in at least 4 case or control 
subjects and with genic burden Benjamini-Hochberg FDR <= 25% (red discs) were used to 
query GeneMANIA36 and retrieve additional protein interaction neighbors, resulting in a 
network of 136 synaptic genes. Genes are depicted as disks; disk centers are colored based 
on rare loss frequency (Freq.SZ and Freq.CT) being prevalent in cases or controls; disk 
borders are colored to mark (i) gene implication in human dominant or X-linked 
neurological or neurodevelopmental phenotype, (ii) de novo mutation (DeN) reported by 
Fromer et al. 28, split between LOF (frameshift, stop-gain, core splice site) and missense or 
amino acid insertion / deletion, (iii) implication in mouse neurobehavioral abnormality. Pre-
synaptic adhesion molecules (NRXN1, NRXN3), post-synaptic scaffolds (DLG1, DLG2, 
DLGAP1, SHANK1, SHANK2) and glutamatergic ionotropic receptors (GRID1, GRID2, 
GRIN1, GRIA4) constitute a highly connected subnetwork with more losses in cases than 
controls.
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Figure 4. Gene Based Manhattan Plot
Manhattan plot displaying the –log10 deviance p-value for (a) CNV losses and (b) CNV 
gains the gene-based test. P-value cutoffs corresponding to FWER < 0.05 and BH-FDR < 
0.05 are highlighted in red and blue, respectively. Loci significant after multiple test 
correction are labeled.
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Figure 5. Manhattan plot of breakpoint-level associations across the Neurexin-1 locus
The manhattan plot (for deletions) represents empirical P-values at each deletion breakpoint. 
CNV tracks display duplications (blue) and deletions (red) detected in cases and controls 
from the PGC SCZ dataset.
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